Skip to Content
MilliporeSigma
  • Implementation of newborn screening for Krabbe disease: population study and cutoff determination.

Implementation of newborn screening for Krabbe disease: population study and cutoff determination.

Clinical biochemistry (2009-03-26)
Joseph J Orsini, Mark A Morrissey, Laura N Slavin, Matthew Wojcik, Chad Biski, Monica Martin, Joan Keutzer, X Kate Zhang, Wei-Lien Chuang, Carole Elbin, Michele Caggana
ABSTRACT

The aim of this study was to develop a newborn screening algorithm for Krabbe disease. We measured the galactocerebrosidase activity of 139,074 anonymous newborns, 56 known carriers, and 16 Krabbe patients using a tandem mass spectrometry method. The activities were converted to percentages of daily mean activity (%DMA), and the results from diseased and normal populations were used to establish cutoffs. The absolute activities for the newborns ranged from 0.17 to 355 micromol/L h (N=139,074) and activities for Krabbe-positive controls ranged from 0.08 to 0.48 micromol/L h (N=16, n=91 measurements) while activities for carriers ranged from 0.28 to 2.71 micromol/L h (N=56, n=72 measurements). Cutoffs were set based on results from Krabbe-positive and carrier controls and the newborn population distribution. The algorithm and cutoffs we propose provided 100% detection of all positive controls with 60/100,000 screen positive results predicted. In the course of this study, one anonymous newborn was predicted to have Krabbe disease based on enzyme activity and subsequent DNA analysis.